Factor XIa Concept

subject area of

• A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction  Journal Articles
• A factor XIa-activatable hirudin-albumin fusion protein reduces thrombosis in mice without promoting blood loss  Journal Articles
• Analysis of Inhibition Rate Enhancement by Covalent Linkage of Antithrombin to Heparin as a Potential Predictor of Reaction Mechanism  Journal Articles
• Are Ticks the Answer to Medical Device-Associated Clotting?  Journal Articles
• Effect of the Factor XIa Inhibitor Asundexian According to Baseline Infarct Pattern and on MRI Covert Infarct Outcomes  Journal Articles
• Factor XIa inhibition as a therapeutic strategy for atherothrombosis  Journal Articles
• Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial  Journal Articles
• Histidine-rich glycoprotein binds DNA and RNA and attenuates their capacity to activate the intrinsic coagulation pathway  Journal Articles
• Histidine-rich glycoprotein binds factor XIIa with high affinity and inhibits contact-initiated coagulation  Journal Articles
• Identification of an alpha-1 antitrypsin variant with enhanced specificity for factor XIa by phage display, bacterial expression, and combinatorial mutagenesis  Journal Articles
• MAA868 locks factor XIa in a zymogen-like state  Journal Articles
• Milvexian for the Prevention of Venous Thromboembolism  Journal Articles
• Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and design.  Journal Articles
• Oral factor xia inhibitor milvexian after a recent acute coronary syndrome: Rationale and design of the phase 3 (Librexia ACS).  Journal Articles
• Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention  Journal Articles
• Reduction of thrombus size in murine models of thrombosis following administration of recombinant α1-proteinase inhibitor mutant proteins  Journal Articles
• Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial  Journal Articles
• Selection and characterization of a DNA aptamer inhibiting coagulation factor XIa  Journal Articles
• Selection and in vitro and in vivo characterization of a Kunitz protease inhibitor domain of protease nexin 2 variant that inhibits factor XIa without inhibiting plasmin  Journal Articles
• Transfusion-Induced Specific Anti–Factor XI Inhibitor in a Patient with Previously Unrecognized Factor XI Deficiency  Journal Articles